Long-term outcomes of hypertrophic cardiomyopathy patients undergoing septal reduction therapies: Results from the NHLBI HCMR registry
Current methods to predict risk of adverse events in hypertrophic cardiomyopathy (HCM) are based on retrospective studies from select tertiary centers. The HCM Registry (HCMR) is a prospective registry, funded by the NHLBI, USA to aid in development of clinical and imaging markers that could improve event predict...